0 Évaluations
ID

14969

Description

Metronomic Poly-chemotherapy for Metastatic CRC; ODM derived from: https://clinicaltrials.gov/show/NCT02280694

Lien

https://clinicaltrials.gov/show/NCT02280694

Mots-clés

Versions (1)
  1. 10/05/2016 10/05/2016 -
Téléchargé le

10 mai 2016

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

  • Plus récent
  • Plus ancien
  • Favori
  • Plus récent
    • Plus récent
    • Plus ancien
    • Favori

    Aucun commentaire

    Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

    Eligibility Colorectal Cancer NCT02280694

    Anglais

    Eligibility Colorectal Cancer NCT02280694

    1 Formulaires  
    Inclusion Criteria
    Description

    Inclusion Criteria

    Alias
    UMLS CUI
    C1512693
    1. histological (or cytological) proof of colorectal carcinoma (crc)
    Description

    Colorectal Carcinoma

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0009402
    2. measurable metastases
    Description

    Neoplasm Metastasis Measurable

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0027627
    UMLS CUI [1,2]
    C1513040
    3. ecog (eastern cooperative oncology group) performance status 0-2
    Description

    ECOG performance status

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1520224
    4. progressing disease following all available chemotherapy treatment lines (including chemotherapy, bevacizumab+/-ziv-aflibercept, and an epidermal growth factor receptor (egfr) inhibitor [if wt(wild type)-kras]
    Description

    Progressive Neoplastic Disease | Chemotherapy Regimen | bevacizumab | ziv-aflibercept | Epidermal growth factor receptor inhibitor | KRAS wt Allele

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0677932
    UMLS CUI [2]
    C0392920
    UMLS CUI [3]
    C0796392
    UMLS CUI [4]
    C3485619
    UMLS CUI [5]
    C1443775
    UMLS CUI [6]
    C1705982
    5. the central-radiologist's confirmation of pd* under the last (previous) line of "conventional treatment" and determination of pfs1, according to recist criteria
    Description

    Progressive Neoplastic Disease | Progression-Free Survival | Response Evaluation Criteria in Solid Tumors

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0677932
    UMLS CUI [2]
    C0242792
    UMLS CUI [3]
    C1709926
    pd (progressive disease) by recist(response evaluation criteria in solid tumors) criteria : a) there is 20% or more relative increment in the sum of diameters of target lesions in comparison with the base line sum, and their absolute increase is 5 mm. or more, or b) there appeared one or more new lesions, or c)there is substantial worsening in non-target disease
    Description

    Progressive Neoplastic Disease Response Evaluation Criteria in Solid Tumors | Target Lesion Identification | Increment Relative | Increase Absolute | New Lesion Identification | Non-Target Lesion Identification Worsening

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0677932
    UMLS CUI [1,2]
    C1709926
    UMLS CUI [2]
    C2986546
    UMLS CUI [3,1]
    C1705117
    UMLS CUI [3,2]
    C0205345
    UMLS CUI [4,1]
    C0442805
    UMLS CUI [4,2]
    C0205344
    UMLS CUI [5]
    C2986548
    UMLS CUI [6,1]
    C2986547
    UMLS CUI [6,2]
    C0332271
    6. age: between 18 and 85
    Description

    Age

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0001779
    7. prior radiotherapy either as adjuvant treatment or for palliation is allowed, unless this was delivered to the only measurable lesion
    Description

    prior radiation therapy Adjuvant therapy | Palliative course of radiotherapy | Measurable lesion

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0279134
    UMLS CUI [1,2]
    C0677850
    UMLS CUI [2]
    C0475092
    UMLS CUI [3]
    C1513041
    8. complete blood counts showing normal values or any toxicity limited to grade 1.
    Description

    Full blood count normal | Mild Adverse Event

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0427692
    UMLS CUI [2]
    C1513302
    9. blood chemistry tests showing liver and renal functions < 1.5 upper normal limit (unl)
    Description

    Whole Blood Chemistry Test | Liver function | Renal function | Upper Limit of Normal

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1254486
    UMLS CUI [2]
    C0232741
    UMLS CUI [3]
    C0232804
    UMLS CUI [4]
    C1519815
    10. absence of any non-hematological toxicity at grade 2 or higher
    Description

    Adverse Event Toxicity Grade Mild Adverse Event

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C2697890
    UMLS CUI [1,2]
    C1513302
    11. the experimental treatment should start within 3 to 7 weeks from the last cycle of conventional treatment
    Description

    Therapies, Investigational | Conventional Treatment

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0949266
    UMLS CUI [2]
    C2945704
    12. the patient is able to understand and ready to sign the informed consent
    Description

    Informed Consent

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0021430
    Exclusion Criteria
    Description

    Exclusion Criteria

    Alias
    UMLS CUI
    C0680251
    1. lack of confirmation of pd (under the pre-study treatment) by the central radiologist
    Description

    Lacking Confirmation of Progressive Neoplastic Disease

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0332268
    UMLS CUI [1,2]
    C0521091
    UMLS CUI [1,3]
    C0677932
    2. any concurrent other active cancer (except basal cell or squamous cell carcinoma of skin and early prostate cancer or dcis- in situ breast cancer)
    Description

    Malignant Neoplasms Concurrent | Basal cell carcinoma | Squamous cell carcinoma of skin | prostate cancer screening | Noninfiltrating Intraductal Carcinoma

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0006826
    UMLS CUI [1,2]
    C0205420
    UMLS CUI [2]
    C0007117
    UMLS CUI [3]
    C0553723
    UMLS CUI [4]
    C0281186
    UMLS CUI [5]
    C0007124
    3. inability to adhere to monthly visits to the oncological unit for evaluation
    Description

    Unable Patient Visit Monthly

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C1299582
    UMLS CUI [1,2]
    C1512346
    UMLS CUI [1,3]
    C0332177
    4. presence of brain metastases
    Description

    Metastatic malignant neoplasm to brain

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0220650
    5. continuous treatment with steroids or with nsaids or with anticoagulants during the last year (except micropirin)
    Description

    Therapeutic procedure | Steroids | Anti-Inflammatory Agents, Non-Steroidal | Anticoagulants | Nu-Seals Aspirin

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0087111
    UMLS CUI [2]
    C0038317
    UMLS CUI [3]
    C0003211
    UMLS CUI [4]
    C0003280
    UMLS CUI [5]
    C0591883
    6. previous radiotherapy to the only site of measurable disease
    Description

    prior radiation therapy Measurable Disease Site

    Type de données

    boolean

    Alias
    UMLS CUI [1,1]
    C0279134
    UMLS CUI [1,2]
    C1513041
    UMLS CUI [1,3]
    C0205145
    7. existence of active peptic ulcer or symptomatic coronary disease
    Description

    Peptic Ulcer | Coronary heart disease

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0030920
    UMLS CUI [2]
    C0010068
    8. existence of chronic inflammatory diseases, such as ulcerative colitis or crohn's disease or rheumatoid arthritis
    Description

    Chronic inflammatory disorder | Ulcerative Colitis | Crohn Disease | Rheumatoid Arthritis

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C1290886
    UMLS CUI [2]
    C0009324
    UMLS CUI [3]
    C0010346
    UMLS CUI [4]
    C0003873
    9. presence of ascites, and/or any other "third space" finding (eg. significant leg edema)
    Description

    Ascites | Leg edema

    Type de données

    boolean

    Alias
    UMLS CUI [1]
    C0003962
    UMLS CUI [2]
    C0235886
    Retour au début de la page

    Similar models

    Eligibility Colorectal Cancer NCT02280694

    1 Formulaires
    Name
    Type
    Description | Question | Decode (Coded Value)
    Type de données
    Alias
    Item Group
    C1512693 (UMLS CUI)
    Colorectal Carcinoma
    Item
    1. histological (or cytological) proof of colorectal carcinoma (crc)
    boolean
    C0009402 (UMLS CUI [1])
    Neoplasm Metastasis Measurable
    Item
    2. measurable metastases
    boolean
    C0027627 (UMLS CUI [1,1])
    C1513040 (UMLS CUI [1,2])
    ECOG performance status
    Item
    3. ecog (eastern cooperative oncology group) performance status 0-2
    boolean
    C1520224 (UMLS CUI [1])
    Progressive Neoplastic Disease | Chemotherapy Regimen | bevacizumab | ziv-aflibercept | Epidermal growth factor receptor inhibitor | KRAS wt Allele
    Item
    4. progressing disease following all available chemotherapy treatment lines (including chemotherapy, bevacizumab+/-ziv-aflibercept, and an epidermal growth factor receptor (egfr) inhibitor [if wt(wild type)-kras]
    boolean
    C0677932 (UMLS CUI [1])
    C0392920 (UMLS CUI [2])
    C0796392 (UMLS CUI [3])
    C3485619 (UMLS CUI [4])
    C1443775 (UMLS CUI [5])
    C1705982 (UMLS CUI [6])
    Progressive Neoplastic Disease | Progression-Free Survival | Response Evaluation Criteria in Solid Tumors
    Item
    5. the central-radiologist's confirmation of pd* under the last (previous) line of "conventional treatment" and determination of pfs1, according to recist criteria
    boolean
    C0677932 (UMLS CUI [1])
    C0242792 (UMLS CUI [2])
    C1709926 (UMLS CUI [3])
    Progressive Neoplastic Disease Response Evaluation Criteria in Solid Tumors | Target Lesion Identification | Increment Relative | Increase Absolute | New Lesion Identification | Non-Target Lesion Identification Worsening
    Item
    pd (progressive disease) by recist(response evaluation criteria in solid tumors) criteria : a) there is 20% or more relative increment in the sum of diameters of target lesions in comparison with the base line sum, and their absolute increase is 5 mm. or more, or b) there appeared one or more new lesions, or c)there is substantial worsening in non-target disease
    boolean
    C0677932 (UMLS CUI [1,1])
    C1709926 (UMLS CUI [1,2])
    C2986546 (UMLS CUI [2])
    C1705117 (UMLS CUI [3,1])
    C0205345 (UMLS CUI [3,2])
    C0442805 (UMLS CUI [4,1])
    C0205344 (UMLS CUI [4,2])
    C2986548 (UMLS CUI [5])
    C2986547 (UMLS CUI [6,1])
    C0332271 (UMLS CUI [6,2])
    Age
    Item
    6. age: between 18 and 85
    boolean
    C0001779 (UMLS CUI [1])
    prior radiation therapy Adjuvant therapy | Palliative course of radiotherapy | Measurable lesion
    Item
    7. prior radiotherapy either as adjuvant treatment or for palliation is allowed, unless this was delivered to the only measurable lesion
    boolean
    C0279134 (UMLS CUI [1,1])
    C0677850 (UMLS CUI [1,2])
    C0475092 (UMLS CUI [2])
    C1513041 (UMLS CUI [3])
    Full blood count normal | Mild Adverse Event
    Item
    8. complete blood counts showing normal values or any toxicity limited to grade 1.
    boolean
    C0427692 (UMLS CUI [1])
    C1513302 (UMLS CUI [2])
    Whole Blood Chemistry Test | Liver function | Renal function | Upper Limit of Normal
    Item
    9. blood chemistry tests showing liver and renal functions < 1.5 upper normal limit (unl)
    boolean
    C1254486 (UMLS CUI [1])
    C0232741 (UMLS CUI [2])
    C0232804 (UMLS CUI [3])
    C1519815 (UMLS CUI [4])
    Adverse Event Toxicity Grade Mild Adverse Event
    Item
    10. absence of any non-hematological toxicity at grade 2 or higher
    boolean
    C2697890 (UMLS CUI [1,1])
    C1513302 (UMLS CUI [1,2])
    Therapies, Investigational | Conventional Treatment
    Item
    11. the experimental treatment should start within 3 to 7 weeks from the last cycle of conventional treatment
    boolean
    C0949266 (UMLS CUI [1])
    C2945704 (UMLS CUI [2])
    Informed Consent
    Item
    12. the patient is able to understand and ready to sign the informed consent
    boolean
    C0021430 (UMLS CUI [1])
    Item Group
    C0680251 (UMLS CUI)
    Lacking Confirmation of Progressive Neoplastic Disease
    Item
    1. lack of confirmation of pd (under the pre-study treatment) by the central radiologist
    boolean
    C0332268 (UMLS CUI [1,1])
    C0521091 (UMLS CUI [1,2])
    C0677932 (UMLS CUI [1,3])
    Malignant Neoplasms Concurrent | Basal cell carcinoma | Squamous cell carcinoma of skin | prostate cancer screening | Noninfiltrating Intraductal Carcinoma
    Item
    2. any concurrent other active cancer (except basal cell or squamous cell carcinoma of skin and early prostate cancer or dcis- in situ breast cancer)
    boolean
    C0006826 (UMLS CUI [1,1])
    C0205420 (UMLS CUI [1,2])
    C0007117 (UMLS CUI [2])
    C0553723 (UMLS CUI [3])
    C0281186 (UMLS CUI [4])
    C0007124 (UMLS CUI [5])
    Unable Patient Visit Monthly
    Item
    3. inability to adhere to monthly visits to the oncological unit for evaluation
    boolean
    C1299582 (UMLS CUI [1,1])
    C1512346 (UMLS CUI [1,2])
    C0332177 (UMLS CUI [1,3])
    Metastatic malignant neoplasm to brain
    Item
    4. presence of brain metastases
    boolean
    C0220650 (UMLS CUI [1])
    Therapeutic procedure | Steroids | Anti-Inflammatory Agents, Non-Steroidal | Anticoagulants | Nu-Seals Aspirin
    Item
    5. continuous treatment with steroids or with nsaids or with anticoagulants during the last year (except micropirin)
    boolean
    C0087111 (UMLS CUI [1])
    C0038317 (UMLS CUI [2])
    C0003211 (UMLS CUI [3])
    C0003280 (UMLS CUI [4])
    C0591883 (UMLS CUI [5])
    prior radiation therapy Measurable Disease Site
    Item
    6. previous radiotherapy to the only site of measurable disease
    boolean
    C0279134 (UMLS CUI [1,1])
    C1513041 (UMLS CUI [1,2])
    C0205145 (UMLS CUI [1,3])
    Peptic Ulcer | Coronary heart disease
    Item
    7. existence of active peptic ulcer or symptomatic coronary disease
    boolean
    C0030920 (UMLS CUI [1])
    C0010068 (UMLS CUI [2])
    Chronic inflammatory disorder | Ulcerative Colitis | Crohn Disease | Rheumatoid Arthritis
    Item
    8. existence of chronic inflammatory diseases, such as ulcerative colitis or crohn's disease or rheumatoid arthritis
    boolean
    C1290886 (UMLS CUI [1])
    C0009324 (UMLS CUI [2])
    C0010346 (UMLS CUI [3])
    C0003873 (UMLS CUI [4])
    Ascites | Leg edema
    Item
    9. presence of ascites, and/or any other "third space" finding (eg. significant leg edema)
    boolean
    C0003962 (UMLS CUI [1])
    C0235886 (UMLS CUI [2])
    Retour au début de la page 

    Aide

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial